Radiopharmaceutical therapy for leptomeningeal metastatic disease

Awarded in 2024
Updated Apr 24, 2025

At a Glance

Patients with leptomeningeal metastatic disease (LMD), the spread of cancer into the fluid that surrounds the brain and spinal cord, can exhibit loss of vision, hearing, speech, and facial movement and sensation. If not treated, LMD will typically cause death within weeks. Current standard treatment for patients with LMD involves radiotherapy that treats LMD and normal tissues of the head and spine. This project will investigate a new therapeutic approach that can more effectively and more safely treat patients with LMD to achieve disease control and improve patient survival while limiting dose to normal tissues of the brain and bone.